NASA astronauts Butch Wilmore and Suni Williams are steadily recovering after spending nine unexpected months aboard the International Space Station (ISS) due to issues with Boeing’s Starliner capsule. Initially intended for an eight-day test flight, the mission extended when Starliner experienced propulsion problems that forced NASA to return the capsule uncrewed in 2023.
The astronauts returned to Earth in March 2025 and have since undergone intensive physical therapy to readjust to gravity. Wilmore, 62, noted the difficulties of re-adapting to Earth's conditions, saying, “Gravity stinks for a period.” Williams, 59, echoed the challenges, highlighting muscle fatigue and delayed energy recovery. Both astronauts spent about two hours daily with NASA’s reconditioning specialists during a standard 45-day rehab period.
Despite lingering issues, such as neck pain for Wilmore and fatigue for Williams, both are now supporting Boeing and NASA operations, helping evaluate the Starliner program and contributing to ISS-related research. Wilmore noted that some of his preexisting physical pain vanished in microgravity but returned immediately upon splashdown.
Boeing has already incurred over $2 billion in costs developing Starliner and is awaiting a key decision from NASA: whether to mandate another uncrewed flight before resuming crewed missions. Williams supports the idea, citing the cautious approach taken by SpaceX and Russia in launching uncrewed missions before sending astronauts.
NASA expects to complete tests of Starliner over the summer, which will determine if it’s ready to fly humans again. Williams and Wilmore continue to be key figures in that assessment as Boeing aims to regain trust in its human spaceflight program.
The Starliner setback adds to Boeing’s ongoing challenges, contrasting with the consistent performance of rival capsules developed by SpaceX. NASA’s upcoming decision will be pivotal for Boeing’s future in space exploration.


Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO
NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings
LG Energy Solution Q2 Profit Plunges 77% Despite Revenue Growth on Weak EV Demand
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency
China 618 Smartphone Sales Drop 13% as Higher Prices Hurt Demand, Huawei Gains Market Share 



